AUL
APLS

AlphaGrep UK Ltd’s Apellis Pharmaceuticals APLS Stock Holding History

AlphaGrep UK Ltd’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$286K Sell
7,120
-1,203
-14% -$25.9K 0.08% 536
2025
Q4 		$209K Buy
+8,323
New +$195K 0.07% 611

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AlphaGrep UK Ltd's APLS Position: Q1 2026 in Review

AlphaGrep UK Ltd reduced its Apellis Pharmaceuticals (APLS) stake by 14% in Q1 2026, selling an estimated $25.9K and leaving 7,120 shares worth $286K. The position accounts for 0.08% of the portfolio, ranked #536.

AlphaGrep UK Ltd first reported a position in APLS in Q4 2025 and has held it in 2 quarters since. 322 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • AlphaGrep UK Ltd held 7,120 shares of Apellis Pharmaceuticals worth $286K as of Q1 2026.
  • AlphaGrep UK Ltd sold 1,203 Apellis Pharmaceuticals shares in Q1 2026, an estimated $25.9K.
  • Apellis Pharmaceuticals made up 0.08% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #536 holding.
  • AlphaGrep UK Ltd first reported a position in Apellis Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 322 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.